Cardiac drugs
Pro Research Analysisby 
Searched over 200M research papers for "cardiac drugs"
Cardiac Drugs: A Comprehensive Overview
Modernized Classification of Cardiac Antiarrhythmic Drugs
The classification of antiarrhythmic drugs has evolved significantly since the original Vaughan Williams framework. This modernized classification retains the original Classes I through IV but introduces subcategories to reflect recent discoveries. For instance, Class I now includes various Na+ current components, while Class II incorporates advances in autonomic signaling. Class III is expanded to include different K+ channel subspecies, and Class IV addresses novel molecular targets related to Ca2+ homeostasis. Additionally, new classes have been introduced to cover channels involved in automaticity, mechanically sensitive ion channels, and connexins controlling electrotonic cell coupling. This updated classification aims to provide a more comprehensive understanding of antiarrhythmic drugs, aiding in both clinical management and future drug development .
Effectiveness of Antiarrhythmic Drugs for Shockable Cardiac Arrest
A systematic review aimed at evaluating the effectiveness of antiarrhythmic drugs for shockable cardiac arrest found limited high-level evidence supporting their use. The review included 14 randomized controlled trials (RCTs) and 17 observational studies. The findings indicated no significant difference in survival to hospital discharge or discharge with good neurological function when comparing antiarrhythmic drugs to placebo. However, lidocaine showed a significant increase in the return of spontaneous circulation compared to placebo. These results highlight the need for further high-quality research to confirm these findings and explore the role of antiarrhythmic drugs in pediatric populations and adults immediately after return of spontaneous circulation (ROSC) .
New Antiarrhythmic Agents: Clinical Efficacy and Side Effects
Several new antiarrhythmic agents, including amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, and verapamil, have shown clinical efficacy in suppressing cardiac arrhythmias. These drugs have been evaluated for their clinical experience, side effects, clinical pharmacology, and electrophysiologic actions. Each of these agents has demonstrated effectiveness in managing various types of cardiac arrhythmias, contributing to the expanding arsenal of antiarrhythmic medications available for clinical use .
Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation
The Stroke Prevention in Atrial Fibrillation Study analyzed the relationship between antiarrhythmic drug therapy and cardiac mortality. The study found that patients receiving antiarrhythmic drugs had a 2.5-fold increase in cardiac mortality and a 2.6-fold increase in arrhythmic death compared to those not receiving these drugs. The risk was particularly high in patients with a history of congestive heart failure, where the relative risk of cardiac death was 4.7. These findings suggest that the risks of antiarrhythmic drug therapy may outweigh the benefits in certain populations, particularly those with pre-existing heart conditions .
Heart Failure Induced by Non-Cardiac Drugs
Non-cardiac drugs can also induce heart failure or exacerbate existing heart conditions. Drugs such as anticancer agents, immunomodulating drugs, antidiabetic medications, and NSAIDs have been associated with adverse cardiovascular effects. For example, anthracyclines can cause cardiomyopathy, and NSAIDs can lead to renal dysfunction and elevated blood pressure, potentially precipitating heart failure. A detailed history of drug exposure is crucial for patients presenting with signs or symptoms of heart failure to identify potential drug-induced causes .
Use of Antiarrhythmic Drugs for Adult Cardiac Arrest
A comprehensive review of the use of antiarrhythmic drugs in adult cardiac arrest found that amiodarone improved survival to hospital admission but not to hospital discharge when compared to lidocaine. The review included 25 studies, with nine being randomized controlled trials. The evidence was insufficient to support or refute the use of lidocaine and other antiarrhythmic agents in the same settings. These findings underscore the need for more robust data to guide the use of antiarrhythmic drugs in cardiac arrest scenarios .
Conclusion
The landscape of cardiac drugs, particularly antiarrhythmic agents, is continually evolving with new classifications, drugs, and evidence emerging. While some drugs show promise in specific scenarios, the overall effectiveness and safety profiles require further investigation. Clinicians must stay informed about these developments to optimize patient outcomes in the management of cardiac arrhythmias and related conditions.
Sources and full results
Most relevant research papers on this topic